Search Results

• • 67 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.

  Authors:Stuart J. Connolly, Ganesan Karthikeyan, Mpiko Ntsekhe, Abraham Haileamlak, Ahmed el- Sayed, Alaa el- Ghamrawy, et al.From:The New England Journal of Medicine (Vol. 387, Issue 11) Peer-Reviewed

  Sept. 15, 202250 words Report

   Citation Only

• Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT)

  Authors:Kanjana S. Perera, Mukul Sharma, Stuart J. Connolly, Jia Wang, Michael R. Gold, Stefan H. Hohnloser, et al.From:American Heart Journal (Vol. 201) Peer-Reviewed

  July 2018433 words Report

   Abstract Only

• Dabigratan versus Warfarin in patients with atrial fibrillation

  Authors:Stuart J. Connolly, Michael D. Ezekowitz, Salim Yusuf, John Eikelboom, Jonas Oldgren, Amit Parekh, et al.From:The New England Journal of Medicine (Vol. 361, Issue 12) Peer-Reviewed

  Sept. 17, 200952 words Clinical report

   Citation Only

• Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation

  Authors:Charles R. Kerr, Karin H. Humphries, Mario Talajic, George J. Klein, Stuart J. Connolly, Martin Green, et al.From:American Heart Journal (Vol. 149, Issue 3) Peer-Reviewed

  Mar. 2005 Article

   Citation Only

• Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the Beta-blocker Length of Stay (BLOS) study`

  Author:Stuart J. ConnollyFrom:JAMA, The Journal of the American Medical Association (Vol. 289, Issue 20) Peer-Reviewed

  May 28, 2003 Author abstract

   Citation Only

• Andexanet alfa for the reversal of factor Xa inhibitor activity

  Authors:Deborah M. Siegal, John T. Curnutte, Stuart J. Connolly, Genmin Lu, Pamela B. Conley, Brian L. Wiens, et al.From:The New England Journal of Medicine (Vol. 373, Issue 25) Peer-Reviewed

  Dec. 17, 201562 words Report

   Citation Only

• Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale; From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators.

  Authors:Anthony P Carnicelli, Hwanhee Hong, Robert P Giugliano, Stuart J Connolly, John Eikelboom, Manesh R Patel, et al.From:American Heart Journal (Vol. 233) Peer-Reviewed

  Mar. 2021445 words Report

   Abstract Only

• Comparison of beta-Blockers, amiodarone plus beta-Blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: The OPTIC Study: A randomized trial

  Authors:Stuart J. Connolly, Paul Dorian, Robin S. Roberts, Michael Gent, Steven Bailin, Eric S. Fain, et al.From:JAMA, The Journal of the American Medical Association (Vol. 295, Issue 2) Peer-Reviewed

  Jan. 11, 200657 words Article

   Citation Only

• Stroke prevention in nonvalvular atrial fibrillation

  Authors:Gregory W. Albers, J. Edwin Atwood, Jack Hirsh, David G. Sherman, Robert A. Hughes, and Stuart J. ConnollyFrom:Annals of Internal Medicine (Vol. 115, Issue 9) Peer-Reviewed

  Nov. 1, 1991 Article

   Citation Only

• A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial

  Authors:Jonathan P. Piccini, Stuart J. Connolly, William T. Abraham, Jeff S. Healey, Benjamin A. Steinberg, Hussein R. Al-Khalidi, et al.From:American Heart Journal (Vol. 199) Peer-Reviewed

  May 2018536 words Article

   Abstract Only

• Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable

  Authors:Stuart J. Connolly, John W. Eikelboom, Jennifer Ng, Jack Hirsh, Salim Yusuf, Janice Pogue, et al.From:Annals of Internal Medicine (Vol. 155, Issue 9) Peer-Reviewed

  Nov. 1, 2011322 words Author abstract, Cli...

   Abstract Only

• Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the [CHADS.sub.2] score: a subgroup analysis of the RE-LY trial

  Authors:Jonas Oldgren, Marco Alings, Harald Darius, Diener Hans-Christoph, John Eikelboom, Michael D. Ezekowitz, et al.From:Annals of Internal Medicine (Vol. 155, Issue 10) Peer-Reviewed

  Nov. 15, 2011354 words Author abstract, Cli...

   Abstract Only

• Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation

  Authors:Paul Dorian, Miney Paquette, David Newman, Martin Green, Stuart J. Connolly, Mario Talajic, et al.From:American Heart Journal (Vol. 143, Issue 6) Peer-Reviewed

  June 2002 Article

   Citation Only

• Implantable cardioverter defibrillators -- for whom?

  Author:Stuart J. ConnollyFrom:The Lancet (Vol. 352, Issue 9125) Peer-Reviewed

  Aug. 1, 1998 Article

   Citation Only

• Implantable cardioverter defibrillators -- for whom?

  Author:Stuart J. ConnollyFrom:The Lancet (Vol. 352, Issue 9125) Peer-Reviewed

  Aug. 1, 199831 words Article

   Abstract Only

• Efficacy of Hospital at Home in Patients with Heart Failure: A Systematic Review and Meta-Analysis

  Authors:Amro Qaddoura, Payam Yazdan-Ashoori, Conrad Kabali, Lehana Thabane, R. Brian Haynes, Stuart J. Connolly, et al.From:PLoS ONE (Vol. 10, Issue 6) Peer-Reviewed

  June 8, 20155,744 words Article 1380LBackground Heart failure (HF) is the commonest cause of hospitalization in older adults. Compared to routine hospitalization (RH), hospital at home (HaH)-substitutive hospital-level care in the patient's...

• Effect of dronedarone on cardiovascular events in atrial fibrillation

  Authors:Stefan H. Hohnloser, Harry J.G.M Crijns, Martin van EIckels, Christophe Gaudin, Richard L. Page, Christian Torp-Pedersen, et al.From:The New England Journal of Medicine (Vol. 360, Issue 7) Peer-Reviewed

  Feb. 12, 200942 words Article

   Citation Only

• Dronedarone for maintenance of sinus rythum in atrial fibrillation or flutter

  Authors:Bramah N. Singh, Stuart J. Connolly, Harry J.G.M. Crijns, Denis Roy, Peter R. Kowey, Alessandro Capucci, et al.From:The New England Journal of Medicine (Vol. 357, Issue 10) Peer-Reviewed

  Sept. 6, 200732 words Clinical report

   Citation Only

• Evolution of the implantable cardioverter defibrillator

  Authors:Eugene Crystal and Stuart J ConnollyFrom:The Lancet (Vol. 359, Issue 9315) Peer-Reviewed

  Apr. 20, 2002 Brief article

   Citation Only

• Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials

  Authors:Greg C. Flaker, Michael Gruber, Stuart J. Connolly, Steven Goldman, Sandra Chaparro, Alec Vahanian, et al.From:American Heart Journal (Vol. 152, Issue 5) Peer-Reviewed

  Nov. 2006 Article

   Citation Only